What you should know:
- Bone Health Technologies (BHT)a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced that the company has raised a new $5 million funding round from leading investment firms including Esplanade Ventures, Berkeley Catalyst Fund, as well as a leading strategic investor and global medical technology provider Terumo Medical. Ella Seitz of Esplanade Ventures and Yushin Yazaki of Terumo were named board observers.
- This influx of capital marks a pivotal moment in BHT’s mission to reshape the bone health of postmenopausal women, and closes just in time for de novo FDA clearance. The funding will support the final stages of development of BHT’s flagship Osteoboost vibration product, which is scheduled to launch later this year.
Osteoboost: the future of bone health management
Osteoboost, a wearable smart device worn as a hip belt, has been clinically shown to protect postmenopausal women against the decline in bone density commonly associated with menopause and aging. Using precise vibrations, Osteoboost activates the body’s natural bone regeneration process, reducing the risk of progression from osteopenia to osteoporosis. During trials, Osteoboost not only significantly slowed bone density loss, but also showed an impressive user adherence rate exceeding 80%, with no serious adverse events reported.
Currently, more than 64 million people in the United States have osteopenia and osteoporosis. Osteoboost stands out as the first FDA-approved, non-pharmacological prescription device designed to address this lucrative $30 billion market. BHT is currently finalizing production and distribution logistics for the imminent public launch of Osteoboost, expected later this year. Those interested in tracking the progress of the launch, including patients and healthcare professionals, are encouraged to join a notification list.
“Bringing a revolutionary prescription medical device to market, de novo, is a difficult journey that requires patience and perseverance,” said Laura Yecies, CEO of Bone Health Technologies. “We chose to validate the science behind Osteoboost through a rigorous clinical trial, so that postmenopausal women and their doctors can have confidence in our data. FDA clearance was the last major external hurdle, and we are now focused on launching later this year. We are grateful to our early investors who believed in our vision and our new investors who grasped the clinical data and recognized the impact we can have for women around the world.
